Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prior Lisa, O'Dwyer Richard, Farooq Abdul Rehman, Greally Megan, Ward Cian, O'Leary Connor, Aslam Razia, Darwish Waseem, Ahmed Nada, Othman Elly Che, Watson Geoffrey, Kelly Deirdre, Gleeson Jack, Kiely Lisa, Hassan Anees, Walsh Elaine M, O'Reilly David, Jones Alfred, Featherstone Hannah, Lim Marvin, Murray Hazel, Hennessy Bryan T, Smyth Lillian M, Leonard Gregory, Grogan Liam, Breathnach Oscar, Calvert Paula, Horgan Anne M, Coate Linda, Jordan Emmet J, O'Mahony Deirdre, Gupta Rajnish, Keane Maccon M, Westrup Jennifer, Duffy Karen, O'Connor Miriam, Morris Patrick G, Kennedy M John, O'Reilly Seamus, McCaffrey John, Kelly Catherine M, Carney Desmond, Gullo Giuseppe, Crown John, Higgins Michaela J, Walsh Paul M, Walshe Janice M
Аннотация
METHODS: This was a national, multi-site, retrospective observational study, including PABC patients treated in 12 oncology institutions from August 2001 to January 2020. Data extracted included information on patient demographics, tumour biology, staging, treatments, and maternal/foetal outcomes. Survival data for an age-matched breast cancer population over a similar time period was obtained from the National Cancer Registry of Ireland (NCRI). Standard biostatistical methods were used for analyses.
RESULTS: We identified 155 patients-71 (46%) were gp-PABC and 84 (54%) were pp-PABC. The median age was 36 years. Forty-four patients (28%) presented with Stage III disease and 25 (16%) had metastatic disease at diagnosis. High rates of triple-negative (25%) and HER2+ (30%) breast cancer were observed. We observed an inferior 5-year overall survival (OS) rate in our PABC cohort compared to an age-matched breast cancer population in both Stage I-III (77.6% vs 90.9%) and Stage IV disease (18% vs 38.3%). There was a low rate (3%) of foetal complications.
CONCLUSION: PABC patients may have poorer survival outcomes. Further prospective data are needed to optimise management of these patients.